医学
化学免疫疗法
肿瘤科
耐火材料(行星科学)
内科学
挽救疗法
淋巴瘤
嵌合抗原受体
化疗
布仑妥昔单抗维多汀
造血干细胞移植
移植
弥漫性大B细胞淋巴瘤
美罗华
免疫疗法
癌症
霍奇金淋巴瘤
物理
天体生物学
作者
Donald C. Moore,Matthew R. Peery,Katherine Tobon,Farah Raheem,Grace Hwang,Lin Alhennawi,Mitchell E. Hughes
标识
DOI:10.1177/10781552221096165
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed/refractory DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI